#VisualAbstract: FOLFOX in combination with nivolumab and trastuzumab improves survival in metastatic ERBB2⁺ esophagogastric adenocarcinoma
Click to read this study in JAMA Oncology.
Click to read this study in JAMA Oncology.
Click to read this study in The Lancet Oncology.
Click to read this study in The Lancet Oncology.
Click to read this study in JAMA Network Open.
1. Nivolumab in combination with chemotherapy or ipilimumab significantly prolonged overall survival compared to chemotherapy alone. 2. Common treatment-related adverse ...
Click to read this study in the European Journal of Cancer.
Click to read this study in the European Journal of Cancer.
Click to read this study in the Journal of Clinical Oncology.
Click to read the study in The Lancet Oncology.
Click to read this study in the Journal of Clinical Oncology.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.